



NATÁLIA TOLEDO

Attorney at Law

+55 21 3550 8547

+55 21 97983 8885

natalia.toledo@lickslegal.com

PRACTICE AREAS

- Food & Drug Law
- Government Contracts & Public Procurements
- Intellectual Property
- Litigation
- Regulatory Law
- Life Sciences

LANGUAGES

- Portuguese
- English

BIOGRAPHY

Natália Toledo has been an attorney at law at Licks Attorneys' Rio de Janeiro office since 2021. Before that, she worked as a legal intern for the team, starting in 2018. Her practice focuses on complex regulatory disputes (both judicial and administrative) and litigation in intellectual property. Ms. Toledo has an extensive background in food and drug law, specially assisting pharmaceutical companies with legal advice and in administrative proceedings before ANVISA (Brazil's FDA).

REPRESENTATIVE CASES

- Assisted a major Brazilian pharmaceutical company with the negotiations and conclusion of a R&D partnership agreement for development of a drug in cooperation with a Brazilian Federal University.

AFFILIATIONS

- Brazilian Bar Association – Rio de Janeiro (OAB/RJ).

EDUCATION

- Bachelor of Laws (LL.B), Pontifical Catholic University of Rio de Janeiro – PUC-Rio (2021).

PUBLICATIONS

- [Novidades do regulamento das PDPs são mesmo novidades? – Parte 1](#), JOTA, 2024;
- [New PDP Regulation: Fresh Start or Same Old thing? – Part 1](#), Lexology, 2024;
- [Cancelamento automático dos produtos de cannabis pela Anvisa](#), JOTA, 2024;
- [Automatic cancellation of Cannabis Products' authorizations by Anvisa:](#)

- [incentive or setback?](#), Lexology, 2024;
- [Mais um passo para a retomada das PDPs: a minuta de norma resolve os erros do passado?](#), JOTA, 2023;
- [Another step towards the return of PDPs: does the draft new regulation solve past mistakes?](#), Lexology, 2023;
- [Prescribing cannabis products only as a last resort](#), Chambers and Partners, 2023;
- [A prescrição de produtos de Cannabis só como última alternativa](#), JOTA, 2023;
- [Indústria de genéricos usa prática ilegal no Brasil para alterar bulas e infringir patentes](#), Migalhas, 2022;
- [O vai e volta da Anvisa na transparência de pedidos de registro de medicamentos](#), JOTA, 2022;
- [O desafio dos biossimilares e a postura do Ministério da Saúde no Brasil](#), Migalhas, 2021.